

# Imaging Timing After Surgery for Glioblastoma (INTERVAL GB)

INTERVAL-GB Collaborative

DOI:

[10.1016/j.bas.2023.102127](https://doi.org/10.1016/j.bas.2023.102127)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

INTERVAL-GB Collaborative 2023, 'Imaging Timing After Surgery for Glioblastoma (INTERVAL GB): A multi-centre, UK and Ireland retrospective cohort study', *Brain and Spine*, vol. 3, no. Supplement 1, 102127. <https://doi.org/10.1016/j.bas.2023.102127>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.


When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Optional Image



1583  
BRAIN AND SPINE 3 (2023) 101794 102127  
IMAGING TIMING AFTER SURGERY FOR GLIOBLASTOMA (INTERVAL GB):  
A MULTI-CENTRE, UK AND IRELAND RETROSPECTIVE COHORT STUDY

Emily Rose Bligh<sup>1</sup>, Conor Gillespie<sup>2</sup>, Michael T.C. Poon<sup>3</sup>, Georgios Solomou<sup>4</sup>,  
Melissa Gough<sup>5</sup>, Abdurrahman I. Islam<sup>6</sup>, Christopher P. Millward<sup>7</sup>,  
Ola Rominiyi<sup>8</sup>, Rasheed Zakaria<sup>9</sup>, Stephen J. Price<sup>4</sup>, Colin Watts<sup>10</sup>,  
Sophie Camp<sup>11</sup>, Thomas C. Booth<sup>12</sup>, Gerard Thompson<sup>13</sup>,  
Samantha J. Mills<sup>14</sup>, Adam Waldman<sup>15</sup>, Paul Brennan<sup>15</sup>,  
Michael D. Jenkinson<sup>7</sup>, INTERVAL-GB Collaborative<sup>161</sup> Department of  
Neurosurgery, Queen Elizabeth University Hospital, Glasgow, United Kingdom;  
<sup>2</sup> Department of Neurosurgery, The Walton Centre NHS Foundation Trust,  
Liverpool, UK, United Kingdom; <sup>3</sup> Usher Institute, The University of Edinburgh,  
Edinburgh, UK, United Kingdom; <sup>4</sup> Department of Clinical Neurosciences, University

of Cambridge, Cambridge, UK, United Kingdom; <sup>5</sup> Department of Neurosurgery,  
Royal Victoria Infirmary, Newcastle upon Tyne, UK, United Kingdom; <sup>6</sup> Division of  
Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and  
Health, University of Manchester, Manchester, UK, United Kingdom; <sup>7</sup> Institute of  
Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK,  
United Kingdom; <sup>8</sup> Department of Oncology & Metabolism, The University of  
Sheffield, Sheffield, UK, United Kingdom; <sup>9</sup> Department of Molecular and Clinical  
Cancer Medicine, University of Liverpool, Liverpool, UK, United Kingdom;  
<sup>10</sup> Institute of Cancer and Genomic Studies, University of Birmingham, Birmingham,  
UK, United Kingdom; <sup>11</sup> Department of Neurosurgery, Imperial College Healthcare  
NHS Trust, London, UK, United Kingdom; <sup>12</sup> School of Biomedical Engineering &  
Imaging Sciences, King's College London, London, UK, United Kingdom;  
<sup>13</sup> Edinburgh Neuro-oncology Translational Imaging Research (ENTIRE), Centre for  
Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK, United Kingdom;  
<sup>14</sup> Department of Neuroradiology, The Walton Centre NHS Foundation Trust,  
Liverpool, UK, United Kingdom; <sup>15</sup> Centre for Clinical Brain Sciences, University of  
Edinburgh, Edinburgh, UK, United Kingdom; <sup>16</sup> Neurology and Neurosurgery  
Interest Group (NANSIG), London, UK, United Kingdom

Oral e-Poster Presentations - Booth 3: Neuro-Oncology A (Malignant glioma),  
September 25, 2023, 1:00 PM - 2:30 PM  
**Background:** The benefit of regular, scheduled follow-up MRI on glioblastoma  
patient management and outcomes is unclear. Our aim was to investigate na-  
tional follow-up MRI surveillance practice after surgery for glioblastoma, assess  
compliance with recommendations from the National Institute for Health and  
Care Excellence (NICE), and determine the association with overall survival (OS)  
and progression-free survival (PFS).  
**Methods:** Multi-centre retrospective observational cohort study of histopatho-  
logically confirmed glioblastoma (operated August 2018-February 2019) who  
received any adjuvant oncological treatment. Follow-up MRI schedules, in-  
dications, and clinical outcomes were collected. Primary objective was to assess  
compliance with NICE recommendations (Post-operative scan <72 hrs, MRI  
every 3-6 months). Secondary objectives were OS and PFS.  
**Results:** 754 patients from 26 neuro-oncology centres were included. Most pa-  
tients had post-operative MRI <72 hours of surgery (88.1%, N=407/462). 28.1%  
of patients had follow-up MRI in accordance with NICE recommendations  
(N=212/754). Median follow-up period was 10.5 months (IQR 5.3-19.4  
months). Median overall survival was 15.1 months (95% CI 12.9-17.3) in the  
scheduled MRI group and 9.1 months (95% CI 7.8-10.4) in the non-compliant  
group. On multivariable cox regression analysis, regular, scheduled MRI was  
independently associated with longer overall survival (HR 1.67, 95% CI 1.33-  
2.10, P<0.001), but not PFS (HR 1.20, 95% CI 0.98-1.47, P=0.074). Having  
three or more scheduled scans in the first 12 months of follow-up was inde-  
pendently associated with increased OS (HR 2.03, 95% CI 1.41-2.94, P<0.001)  
and PFS (HR 1.67, 95% CI 1.25-2.23, P<0.001).  
**Conclusions:** Following regular scheduled surveillance follow-up MRI for glio-  
blastoma is associated with longer overall survival. Prospective trials are needed  
to determine whether regular or symptom-directed MRI influences survival  
outcomes and quality of life.

38  
BRAIN AND SPINE 3 (2023) 101794 102128  
THE ROLE OF P16 IMMUNOHISTOCHEMISTRY AS A PROGNOSTIC  
BIOMARKER IN MENINGIOMAS

Felix Behling<sup>1</sup>, Maria-Elisa Di Francesco<sup>1</sup>, Christina-Katharina Fodi<sup>1</sup>,  
Jürgen Honegger<sup>1</sup>, Marcos Tatagiba<sup>1</sup>, Ghazaleh Tabatabai<sup>1</sup>,  
Jens Schittenhelm<sup>1</sup>. <sup>1</sup> University Hospital Tübingen, Tübingen, Germany

Oral e-Poster Presentations - Booth 3: Neuro-Oncology B (Meningiomas &  
Metastasis), September 26, 2023, 1:00 PM - 2:30 PM  
**Background:** Despite best clinical management many patients suffering from  
meningioma experience tumor recurrence. During the last decades efforts have  
been made to improve the prognostic stratification regarding meningioma  
recurrence. In many other tumor entities, loss of p16 is associated with tumor  
progression. Evaluation of p16 staining for routine diagnostics and prognostic  
significance to identify meningiomas at risk for recurrence is of clinical interest.  
**Methods:** In this retrospective single-institutional study the immunohisto-  
chemical staining for p16 was analyzed in 397 paraffin-embedded meningioma  
samples. The distribution and association with tumor grading, clinical data and  
progression-free survival according to follow-up MRI were assessed.  
**Results:** Of 397 meningioma samples 69 tumors were immunopositive for p16